VN Research & Consulting
 Like us on facebook  Follow us on twitter  Follow us on LinkedIn  IndiaNotes on Google Plus  IndiaNotes on Pinterest  IndiaNotes on Stumbleupon  Subscribe to our feeds


Stocks  A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Go
Feedback
You are here : IndiaNotes >> Research & Analysis >> Companies >> Sun Pharmaceutical Industries Ltd. >> Research

Sun Pharmaceutical Industries Q2FY18 in line; Recall of ANDAs could be precursor to resolution; Reduce

Prabhudas Lilladher | 16 Nov, 2017  | Follow Author | Add to my Favourites 
  • Rate this article
    (Average Rating 5.0 Based on 1 ratings)


Sun pharma retains its guidance of single-digit decline in sales with 20-22% EBITDA margin. While SUNP had 20% effective tax rate in Q1FY18 and guided for higher tax rate in FY18E, they expects there could be lower tax rate with 10% and 14% tax rate in Q2FY18 and H1FY18.


Link to the PDF



logo
BSE
578.00 -0.10
(-0.02%)
NSE
579.20 +1.50
(0.26%)
Read More
About Prabhudas Lilladher

Prabhudas Lilladher has a nationwide distribution network, consisting of branches, franchisees and associates, providing a comprehensive gamut of financial services in the Institutional and Retail domain. Their services includes Equity, derivatives; margin funding, mutual funds, PMS, IPOs and online trading.

 

For more information please write in to [email protected]

Disclaimer: The author has taken due care and caution to compile and analyse the data. The opinions expressed above are only the views of the author, and not a recommendation to buy or sell. Neither the author nor IndiaNotes.com accept any liability whatsoever arising from the use of any of the above contents.




Technical Calls

What are technical calls?

Other Articles


Have a question?